Comparison
Both are GHRH analogues acting on the pituitary GHRH receptor — Sermorelin is the shorter, more physiological 1–29 sequence with short half-life, while CJC-1295 is a modified analogue with significantly extended half-life designed for less frequent dosing.
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Full name | CJC-1295 (modified GHRH analogue) | Sermorelin (GHRH 1–29 analogue) |
| Sequence | Modified GHRH with substitutions at positions 2, 8, 15, 27 for stability | First 29 amino acids of endogenous GHRH (1–29) |
| Half-life (no DAC) | ~30 minutes (CJC-1295 without DAC) | ~10–20 minutes (reported) |
| Half-life (with DAC) | ~6–8 days (CJC-1295 with DAC; once-weekly dosing) | No DAC formulation |
| Common reported doses | 1–2 mg/week (with DAC); 100–300 mcg/injection (without DAC) | 200–500 mcg per injection, nightly |
| GH pulse pattern | With DAC: sustained blunted elevation; without DAC: pulsatile | Pulsatile (amplifies natural GH pulses) |
| Regulatory history | Research compound; not approved | Historically FDA-approved (Geref, withdrawn 2008 for commercial reasons) |
Sermorelin and CJC-1295 act on the same target — the pituitary GHRH receptor (GHRHR) — and both produce GH release by mimicking the action of endogenous growth hormone-releasing hormone. The fundamental difference between them is engineering: Sermorelin is the first 29 amino acids of endogenous GHRH, retaining close structural fidelity to the natural hormone; CJC-1295 is a synthetic GHRH analogue with amino acid substitutions at positions 2, 8, 15, and 27 that dramatically improve resistance to enzymatic degradation and extend half-life.
The most significant practical consequence of this structural difference is dosing frequency. Sermorelin, with its ~10–20 minute half-life, is administered nightly (and sometimes twice or three times daily in some reported protocols) and requires consistent daily management. CJC-1295 without DAC has an improved but still short half-life (~30 minutes); CJC-1295 with DAC (Drug Affinity Complex) — which enables covalent albumin binding — extends half-life to approximately 6–8 days, enabling once-weekly injection.
The DAC modification is a critical distinction within the CJC-1295 category itself. CJC-1295 with DAC produces a sustained, blunted GH elevation profile rather than a discrete pulsatile GH release. Some researchers prefer this for IGF-1 elevation consistency; others specifically prefer CJC-1295 without DAC (sometimes also called "Modified GRF 1-29" or "Mod GRF 1-29") to maintain a more physiological pulsatile pattern, which is closer to the profile produced by Sermorelin.
Sermorelin's close structural identity to endogenous GHRH (1–29) is frequently cited as a reason to prefer it for research contexts where maintaining a physiological GH pulse pattern is important. The naturally pulsatile GH release — amplified but not fundamentally altered in character — is considered by some researchers to be preferable to the sustained blunted elevation produced by CJC-1295 with DAC.
CJC-1295 (without DAC) / Mod GRF 1-29 also preserves pulsatile GH release and is considered the closer comparator to Sermorelin in terms of GH pulse character. The difference between these two in practice is primarily stability and half-life: CJC-1295 without DAC has a longer stable half-life than Sermorelin, though both are administered by injection for each desired GH pulse.
Both compounds are subject to somatostatin (SRIH) suppression — the endogenous inhibitor of GH release. When somatostatin tone is high (post-meal, elevated blood sugar, stress), both Sermorelin and CJC-1295 will produce a blunted GH response. This is why fasted, pre-sleep administration is the commonly reported protocol for both — aligning injection with periods of low somatostatin and high GH pulse probability.
Both CJC-1295 and Sermorelin combine synergistically with GHRP peptides (Ipamorelin, GHRP-2, GHRP-6) for amplified GH release. The Ipamorelin / CJC-1295 stack is the most commonly reported GH secretagogue combination in research communities. Sermorelin + Ipamorelin is also a documented combination, with the advantage of Sermorelin's closer physiological character.
Sermorelin (as Geref, Serono) was historically FDA-approved for the treatment of GH deficiency in children. It was withdrawn from the market in 2008 for commercial reasons unrelated to safety. This regulatory history provides a degree of clinical reference data that CJC-1295 — a purely synthetic research compound — does not have. CJC-1295 has not been through clinical trials for any approved indication.
CJC-1295 — Reported side effects in research and anecdotal accounts include injection site reactions, water retention, transient flushing, and tingling or numbness in extremities consistent with GH/IGF-1 elevation. With the DAC formulation, the sustained GH elevation may produce more persistent edema than pulsatile dosing approaches.
Sermorelin — Reported side effects in research and anecdotal accounts include injection site discomfort, flushing, and transient headache. Its clinical trial history established a favourable human safety profile. The short half-life means that any side effects are typically transient and resolve quickly.
Combining CJC-1295 and Sermorelin would be redundant — both act at the GHRH receptor, and co-administering two GHRH analogues would not produce additive benefit. The appropriate combination approach is to pair either GHRH analogue with a GHRP (Ipamorelin, GHRP-2) for complementary receptor pathway activation and synergistic GH release.
The CJC-1295 / Ipamorelin combination is covered in depth in the CJC-IPA stack reference.
Researchers commonly choose Sermorelin when a physiologically close GHRH analogue with a well-documented clinical history is preferred, when nightly pulsatile GH stimulation is the objective, or when the compound is being used alongside a GHRP in a research protocol.
Researchers commonly choose CJC-1295 without DAC when improved stability over Sermorelin is desired while maintaining pulsatile GH release. This formulation is often paired with Ipamorelin in the most widely reported GH stack.
Researchers commonly choose CJC-1295 with DAC when dosing convenience is a priority and sustained IGF-1 elevation is acceptable — the once-weekly injection schedule is a significant practical advantage for long-duration research protocols.
Modified GRF 1-29 (Mod GRF 1-29) is another name for CJC-1295 without DAC. It refers to the same amino acid-substituted GHRH 1-29 analogue with improved stability but without the Drug Affinity Complex that enables albumin binding and week-long half-life. The naming can cause confusion: "CJC-1295" in some research community contexts specifically means "CJC-1295 with DAC" (the long-acting version), while "Mod GRF 1-29" or "CJC-1295 without DAC" refers to the pulsatile-acting version.
Sermorelin (Geref, Serono) was withdrawn in 2008 for commercial reasons — market forces and the availability of recombinant GH — not safety concerns. Its historical FDA approval provides a clinical reference base that no other GHRH analogue has. The withdrawal was not associated with adverse safety data, and Sermorelin continues to be used in anti-aging and GH research contexts.
CJC-1295 with DAC, due to its sustained GH elevation profile, tends to produce a more consistent and sustained IGF-1 elevation compared to the pulsatile approach of Sermorelin or CJC-1295 without DAC. Whether this is an advantage depends on the research objective: sustained IGF-1 elevation may be preferable for body composition and anabolic research, while pulsatile patterns more closely mirror physiological GH secretion.
Related Comparisons
Peptide Profiles